Equity Research Analysis: Baird Medical Investment Holdings Ltd (BDMD)
|Blank Capital Research Unit|Spot: $1.80
Price$1.80
Composite Score57.2/100
RatingHOLD (3★)
Rank#1002 OF 7,333
Market Cap$0
IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1002
Positioning
Market Dominance
Manufacturing
Medical Equipment
$0
Pending
Detailed business profile pending verification.
Headcount
—
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = BDMD ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BDMD Baird Medical Investment Holdings Ltd | 57 | 83 | 87 | 16 | 3.5x | 1.1x | 127.1% | 64.6% | 88.2% | 41.3% | 34.0% | - | - | 52.0x | $0 | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Baird Medical Investment Holdings Ltd (BDMD) receives a "Hold" rating with a composite score of 57.2/100. It ranks #1002 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
HQ Base
SHEUNG WAN,
Lagging peers — losers tend to keep underperforming
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for BDMD.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 83 | 95 | -12DRAG |
| MOMENTUM | 16 | 6 | +10ALPHA |
| VALUATION | 87 | 92 | -5NEUTRAL |
| INVESTMENT | 30 | 39 | -9DRAG |
| STABILITY | 33 | 19 | +14ALPHA |
| SHORT INT | 89 | 99 | -10DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 78.6% vs WACC 7.8% (spread +70.8%)
GM 88% vs sector 44%, OM 41% vs sector 3%
Capital turnover 2.12x, R&D intensity 16.7%
Rev growth N/A
Interest coverage 26.6x, Net debt/EBITDA 1.1x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Baird Medical Investment Holdings Ltd (BDMD) as a Hold with a composite score of 57.2/100 at a current price of $1.80. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
Baird Medical Investment Holdings Ltd holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 57.2/100 places it at rank #1002 in our full universe.
Wide
Medium
Exemplary
Undervalued
Gross margins of 88% signal strong pricing power.
Returns on equity of 127.1% exceed cost of capital.
Value factor score of 87 suggests attractive pricing.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
Baird Medical Investment Holdings Ltd represents a hold based on multi-factor quantitative performance.
Our model assigns Baird Medical Investment Holdings Ltd a Hold rating, with a composite score of 57.2/100 and 3 out of 5 stars. Ranked #1002 of 7,333 stocks, BDMD presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
BDMD earns a quality score of 83/100, indicating above-average business quality. The company reports a return on equity of 127.1% (sector avg: -1.9%), gross margins of 88.2% (sector avg: 44.1%), net margins of 34.0% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
BDMD carries a solid value score of 87/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include a P/E ratio of 3.47x, an EV/EBITDA of 1.15x, a P/B ratio of 1.44x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
Baird Medical Investment Holdings Ltd's investment score of 30/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of 64.6% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Baird Medical Investment Holdings Ltd is experiencing notably weak momentum with a score of just 16/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 0.22 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
BDMD's stability score of 33/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.22 and a debt-to-equity ratio of 52.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
BDMD's short interest factor score of 89/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include elevated leverage (D/E: 52.00x), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $0, Baird Medical Investment Holdings Ltd benefits from the generally lower volatility and deeper liquidity associated with its size class.
Baird Medical Investment Holdings Ltd is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1002 of 7,333 overall (86th percentile). Key comparisons include ROE of 127.1% exceeding the -1.9% sector median and operating margins of 41.3% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While BDMD currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Short Int. (89) vs Momentum (16) — closing this gap could shift the rating.
EV/EBITDA 90% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 6787% BELOW SECTOR MEDIAN
Gross Margin 100% ABOVE SECTOR MEDIAN (FAVORABLE)
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation for three major clinical conferences this quarter. These events are pivotal to the company's expansion, providing U.S. clinicians direct access to its innovative needle-based therapies for thyroid conditions.
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the strategic commercial deployment of its technology at Bakersfield Memorial Hospital in California. This launch represents the first ablation case for Benign Thyroid Tumor (or "of its kind") in the vital central California hub of the San Joaquin Valley. This development reinforces Baird Medical's commitment to accel
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful conclusion of its Gynecological Microwave Ablation Masterclass in Shanghai. Led by Dr. Xiaoming Gong of Weheal, the program offered a rigorous curriculum designed to advance procedural expertise in the treatment of benign gynecological conditions using the Company's proprietary technology.
Above 50MA
37.18%
Net New Highs
+51081